TriSalus Life Sciences (NASDAQ:TLSI) Earns “Buy” Rating from Roth Mkm

TriSalus Life Sciences (NASDAQ:TLSI)‘s stock had its “buy” rating reaffirmed by stock analysts at Roth Mkm in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $11.00 price objective on the stock. Roth Mkm’s target price would suggest a potential upside of 112.60% from the company’s current price.

Several other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 target price on the stock. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price for the company. Finally, Canaccord Genuity Group lowered their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Buy” and a consensus price target of $11.79.

TriSalus Life Sciences Trading Up 0.3 %

TLSI traded up $0.01 during trading hours on Friday, hitting $5.17. 6,785 shares of the company’s stock were exchanged, compared to its average volume of 17,977. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $10.42. The firm has a 50 day moving average of $4.48 and a 200 day moving average of $4.77. The firm has a market cap of $157.76 million, a P/E ratio of -2.08 and a beta of 0.51.

Insider Activity

In other news, major shareholder Equity Ab Frankenius bought 62,972 shares of the stock in a transaction dated Tuesday, December 17th. The shares were acquired at an average price of $3.97 per share, with a total value of $249,998.84. Following the completion of the acquisition, the insider now directly owns 6,230,748 shares in the company, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought a total of 70,012 shares of company stock valued at $281,235 over the last quarter. Corporate insiders own 32.80% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at about $66,000. Virtu Financial LLC acquired a new position in TriSalus Life Sciences during the third quarter worth about $92,000. Vestcor Inc acquired a new position in TriSalus Life Sciences during the third quarter worth about $108,000. MSD Partners L.P. acquired a new position in TriSalus Life Sciences during the third quarter worth about $184,000. Finally, Geode Capital Management LLC raised its position in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.